Status:
COMPLETED
Return of First-phase Insulin Secretion in Type 2 Diabetes is Associated With Depletion of Pancreas Lipid
Lead Sponsor:
University of Alabama at Birmingham
Conditions:
Type 2 Diabetes Mellitus
Eligibility:
All Genders
35-65 years
Phase:
NA
Brief Summary
The hypothesis for this study is that pancreas lipid will be more closely associated with first-phase beta-cell response in African-Americans than in European-Americans, both at baseline and in respon...
Detailed Description
The decline in first-phase insulin secretion is a key event in the etiology of type 2 diabetes (T2D). Although the cause of beta-cell failure is not clear, "lipotoxicity" has been proposed. Bariatric ...
Eligibility Criteria
Inclusion
- Diagnosed with Type 2 Diabetes within the past 10 years
- Treated with diet, Metformin, or dipeptidyl peptidase 4 (DPP-IV) inhibitors
- Adult men and women age 35-65 yr
- Have a Hemoglobin A1c \<7.0
- African American or European American race
- Will be overweight (BMI 25-45 kg/m2) but have a stable BMI (\<5 kg change in the past 6 months)
Exclusion
- Use of glucocorticoids
- Estimated glomerular filtration rate \<60
- Alanine aminotransferase \>2.5-fold above the normal upper limit
- Tobacco or recreational drug use
- Unable to undergo MRI
Key Trial Info
Start Date :
October 9 2018
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 31 2023
Estimated Enrollment :
65 Patients enrolled
Trial Details
Trial ID
NCT03430310
Start Date
October 9 2018
End Date
July 31 2023
Last Update
October 24 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
The University of Alabama at Birmingham
Birmingham, Alabama, United States, 35294